Discovery Screening Reduces Attrition by An Order of Magnitude

Discovery Screening Reduces Attrition by An Order of Magnitude 

Lack of bioavailability and other adverse pharmacokinetic properties caused 40% attrition in 1992. However, this attrition was reduced by an order of magnitude by 2000 to 10%. This resulted in a substantial rise in the relative impact of adverse safety to one-third of attrition, whereas lack of efficacy had mildly less impact [1]. The basis of the decreased pharmacokinetic attrition may be reasonably attributable to the introduction of in vitro screening in drug discovery. 

---